Tamoxifen-induced tissue factor pathway inhibitor reduction: a clue for an acquired thrombophilic state?


Erman M., Abali H., ORAN B., Haznedaroglu I., Canpinar H., KİRAZLI Ş., ...Daha Fazla

ANNALS OF ONCOLOGY, cilt.15, sa.11, ss.1622-1626, 2004 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 15 Sayı: 11
  • Basım Tarihi: 2004
  • Doi Numarası: 10.1093/annonc/mdh437
  • Dergi Adı: ANNALS OF ONCOLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.1622-1626
  • Anahtar Kelimeler: breast cancer, hemostasis, hypercoagulability, tamoxifen, TFPI, venous thromboembolism, ACTIVATED PROTEIN-C, SYSTEMIC-LUPUS-ERYTHEMATOSUS, COMBINED ORAL-CONTRACEPTIVES, HORMONE REPLACEMENT THERAPY, FACTOR-V-LEIDEN, BREAST-CANCER, ADJUVANT THERAPY, VENOUS THROMBOSIS, ANTITHROMBIN-III, BLOOD-COAGULATION
  • Hacettepe Üniversitesi Adresli: Evet

Özet

Background: Current understanding of hemostatic systems enables us to better explore the enigmatic pathobiology of tamoxifen (TAM)-induced thrombotic diathesis. We have therefore aimed to assess the hemostatic changes in breast cancer patients receiving TAM on an adjuvant basis.